Ancora Advisors’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Ancora Advisors’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,000	Closed	-$69K	–	2259
2022 Q3	$69K	Hold	7,000	–	–	﹤0.01%	996
2022 Q2	$68K	Hold	7,000	–	–	﹤0.01%	1079
2022 Q1	$68K	Hold	7,000	–	–	﹤0.01%	1141
2021 Q4	$68K	Hold	7,000	–	–	﹤0.01%	1139
2021 Q3	$68K	Hold	7,000	–	–	﹤0.01%	1088
2021 Q2	$68K	Buy	+7,000	New	+$68.8K	﹤0.01%	1006

Other funds holding EBAC

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Ancora Advisors's EBAC Position: Q4 2022 in Review

Ancora Advisors sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q4 2022, closing a stake of 7,000 shares — an estimated $69K sold.

Ancora Advisors first reported a position in EBAC in Q2 2021 and held it in 6 quarters. The position peaked at $69K in Q3 2022. 50 funds tracked by Wall St. Rank hold EBAC as of Q4 2022.

Ancora Advisors reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Ancora Advisors sold 7,000 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q4 2022, an estimated $69K.
Ancora Advisors first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q2 2021 and held it in 6 quarters.
Ancora Advisors's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $69K in Q3 2022.
50 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q4 2022.

Based on Ancora Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.